{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Number of participants with drug-related adverse events. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.","groups":[{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks","id":"OG000","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)"},{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks","id":"OG001","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in Part A","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose (up to approximately 6 months)","title":"Number of Participants With Drug-Related Adverse Events - Part A","type":"PRIMARY","unitOfMeasure":"Participants"}